A team of Dutch researchers has published results of a small study in­ves­ti­gat­ing the impact of Darzalex treat­ment on immuno­glob­u­lin levels in multiple myeloma patients.

In their study, the researchers focus in particular on how the levels of a patient’s un­in­volve­d immuno­glob­u­lins are affected by treat­ment with Darzalex.

Uninvolved immuno­glob­u­lins in myeloma patients are immuno­glob­u­lins that have a type dif­fer­en­t from any mono­clonal immuno­glob­u­lin made by a patient’s myeloma cells.

Someone with IgG multiple myeloma, for example, has myeloma plasma cells that produce mono­clonal immuno­glob­u­lin G (IgG). For this myeloma patient, the …

Results of a recent Greek study indicate that levels of a multiple myeloma patient’s “un­in­volved” im­mu­no­glob­u­lins at the time of diag­nosis may have an impact on the patient’s prognosis.

The human body produces a variety of different im­mu­no­glob­u­lins, which are proteins used by the body to fight infections.  In healthy people, the blood levels of the different im­mu­no­glob­u­lins fall within certain known ranges.

Multiple myeloma patients, however, typically overproduce one type of im­mu­no­glob­u­lin, also called the monoclonal (M)-protein, which is found at higher-than-normal levels in a myeloma patients' blood.

The im­mu­no­glob­u­lins that …